2 recruiting, 1 active not recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow HGG: new trials by email Literature Review of HGG trials Research Report on HGG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma NRG-103 - HGG, High Grade Glioma (III or IV) | Phase 1 | Recruiting | Neuregen Therapeutics Co., Ltd. | 24 | 2026-07-09 | 2026-07-17 |
| Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy Focused Ultrasound Next Generation Dome Helmet, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension - GBM, Glioblastoma Multiforme (GBM) | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-06-04 | 2025-09-17 |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors PF-07799544, PF-07799933 - Melanoma, Glioma | Phase 1 | Active not recruiting | Pfizer | 148 | 2022-11-30 | 2026-09-01 |
Glioma (3) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Melanoma (1) · Neoplasms (1) · Thyroid Neoplasms (1)
Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Astrocytoma (1) · Bronchial Neoplasms (1)
Neuregen Therapeutics Co., Ltd. (1) · Pfizer (1) · Sunnybrook Health Sciences Centre (1)
Canada (2) · China (2) · Australia (1) · Brazil (1) · Israel (1) · Japan (1) · United States (1)
Nir Lipsman (1)